LitAlert ~~ GeneLit.com

    • Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.
    • Pak LM, Gaither R, Rosenberg SM, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Snow C, Collins LC, King TA, Partridge AH.
    • Breast Cancer Res Treat. 2020 Nov 26. doi: 10.1007/s10549-020-06027-0. Epub ahead of print.
    • Beyond the AJR: "Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk".
    • Lowry KP, Sippo DA.
    • AJR Am J Roentgenol. 2020 Nov 25. doi: 10.2214/AJR.20.25138. Epub ahead of print.
    • Commentary

    Original research:

    Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.

    • Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC.
    • Yang H, Liu Z, Wang Y, Li J, Li R, Wang Q, Hu C, Jiang H, Wu H, Song L, Bai Y.
    • Ther Adv Med Oncol. 2020 Nov 11;12:1758835920970845. doi: 10.1177/1758835920970845.
    • Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients.
    • Mighri N, Hamdi Y, Boujemaa M, Othman H, Ben Nasr S, El Benna H, Mejri N, Labidi S, Ayari J, Jaidene O, Bouaziz H, Ben Rekaya M, M'rad R, Haddaoui A, Rahal K, Boussen H, Boubaker S, Abdelhak S.
    • Front Genet. 2020 Nov 6;11:552971. doi: 10.3389/fgene.2020.552971.
    • Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of BRCA1/2 mutation status.
    • Huang X, Liu JQ, Zhou YD, Xu Y, Chen C, Wang X, Cao X, Yao R, Sun Q.
    • Ann Transl Med. 2020 Sep;8(18):1183. doi: 10.21037/atm-20-5996.
    • Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications.
    • Romero I, Leskelä S, Mies BP, Velasco AP, Palacios J.
    • EJC Suppl. 2020 Aug 22;15:1-15. doi: 10.1016/j.ejcsup.2020.02.001.